Stock Traders Buy Large Volume of 23andMe Call Options (NASDAQ:ME)

23andMe Holding Co. (NASDAQ:ME) was the target of unusually large options trading on Wednesday. Stock traders acquired 7,134 call options on the company. This represents an increase of approximately 812% compared to the typical daily volume of 782 call options.

23andMe Stock Down 4.3 %

Shares of NASDAQ:ME opened at $1.76 on Friday. The business’s 50 day moving average is $2.59 and its 200 day moving average is $3.99. The stock has a market cap of $47.22 million, a P/E ratio of -0.11 and a beta of 1.19. 23andMe has a 52-week low of $1.34 and a 52-week high of $12.76.

23andMe (NASDAQ:ME) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) earnings per share (EPS) for the quarter. 23andMe had a negative return on equity of 170.07% and a negative net margin of 183.39%.

Institutional Investors Weigh In On 23andMe

Several large investors have recently modified their holdings of ME. Geode Capital Management LLC boosted its stake in shares of 23andMe by 0.7% during the third quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after purchasing an additional 28,252 shares in the last quarter. FMR LLC boosted its position in 23andMe by 24.0% during the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after acquiring an additional 192,099 shares in the last quarter. Shay Capital LLC boosted its position in 23andMe by 71.7% during the 4th quarter. Shay Capital LLC now owns 702,530 shares of the company’s stock valued at $2,283,000 after acquiring an additional 293,358 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of 23andMe in the 4th quarter valued at $49,000. Finally, MassMutual Private Wealth & Trust FSB bought a new position in shares of 23andMe in the 4th quarter worth $40,000. Institutional investors own 36.10% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 23andMe in a report on Friday, March 7th.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.